Join
Live feed
·
PRReleasevia Quantisnow
Channel Therapeutics Corporation logo

Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models

ByQuantisnow·Wall Street's wire, on your screen.
CHRO· Channel Therapeutics Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CHRO (Channel Therapeutics Corporation) and more on Quantisnow.